Adverse cutaneous reactions to epidermal growth factor receptor inhibitors - A study of 14 patients;Reacções cutâneas adversas aos inibidores do receptor do factor de crescimento epidérmico - Estudo de 14 doentes

Anais Brasileiros de Dermatologia

Volumn 86, Issue 3, 2011, Pages 483-490

  Santiago, Felicidade ^a   Gonçalo, Margarida ^a   Reis, José Pedro ^a   Figueiredo, Américo ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Drug eruptions; Drug toxicity; Epidermal growth factor; Receptor

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BENZOYL PEROXIDE; CETUXIMAB; CORTICOSTEROID; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; METRONIDAZOLE; MINOCYCLINE;

ADULT; AGED; ANGIOMA; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; HUMAN; LUNG CANCER; MALE; MELANOCYTIC NEVUS; PAPULE; PARONYCHIA; PUSTULE; PYOGENIC GRANULOMA; TELANGIECTASIA; TREATMENT RESPONSE; XEROSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG ERUPTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 79960059394     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962011000300010     Document Type: Article

References (25)

1. Deslandres M, Sibaud V, Chevreau C, Delord JP. Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors. Ann Dermatol Venereol. 2008; Spec No 1:16-24.
2. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425-33.
3. Roé E, García Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol. 2006;55:429-37.
4. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55:657-70.
5. Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett. 2007;12:1-5.
6. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317-26.
7. Nanney LB, Stoscheck CM, King JR, Underwood RA, Holbrook KA. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol. 1990;94:742-8.
8. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803-12.
9. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11:689-708.
10. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol. 2009;16:16-26.
11. Guhl G, González-de Arriba A, Daudén E. Epidermal growth factor receptor inhibitors side effects. Actas Dermosifiliogr. 2006;97:296-310.
12. Varela P, Gonçalo M, Moura C, Barroso A. Reacções Cutâneas Adversas aos Inibidores do EGFR- Receptor do Factor de Crescimento Epidérmico. Soc Port Dermatol Venereol. 2007;65:451-462.
13. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous sideeffects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491-500.
14. Dewitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol. 2007;56:500-5.
15. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous sideeffects in cancer patients treated with the antiepidermal growth factor receptor anti body C225. Br J Dermatol. 2001;144:1169-76.
16. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009;4:107-19.
17. Lee MW, Seo CW, Kim SW, Yang HJ, Lee HW, Choi JH, et al. Cutaneous side effects in nonsmall cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol. 2004;84:23-6.
18. Fox LP. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol. 2007;56:460-5.
19. Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, et al. Cutaneous sideeffects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009;161:515-21.
20. Bennani-Lahlou M, Mateus C, Escudier B, Massard C, Soria JC, Spatz A, et al. Eruptive nevi associated with sorafenib treatment. Ann Dermatol Venereol. 2008;135:672-4.
21. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60:299-305.
22. Cowen EW. Epidermal growth factor receptor inhibitors: a new era of drug reactions in a new era of cancer therapy. J Am Acad Dermatol. 2007;56:514-7.
23. Segaert S, Van Cutsem E. Clinical management of EGFRI dermatologic toxicities: the European perspective. Oncology (Williston Park). 2007;21:22-6.
24. de Noronha, Menezes NM, Lima R, Moreira A, Varela P, Barroso A, Baptista A, et al. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients. Eur J Dermatol. 2009;19:248-51.
25. Lynch TJ JR, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12:610-21.